Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Duncan

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2005
Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugsEdward A Weinstein, Takahiro Yano, Lin-Sheng Li, et al.
Nature Reviews. Drug Discovery|October 6, 2015
Hit and lead criteria in drug discovery for infectious diseases of the developing worldKei Katsuno, Jeremy N Burrows, Ken Duncan, et al.
Bioorganic & Medicinal Chemistry Letters|April 10, 2007
Evaluation of N-(phenylmethyl)-4-[5-(phenylmethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-4-yl]benzamide inhibitors of Mycobacterium tuberculosis growthMichael D Wall, Michael Oshin, Gavin A C Chung, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 24, 2004
Differential gene expression identifies novel markers of CD4+ and CD8+ T cell activation following stimulation by Mycobacterium tuberculosisJacqueline M Cliff, Iryna N J Andrade, Rohit Mistry, et al.
The Journal of Infectious Diseases|January 6, 2007
Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosisRohit Mistry, Jacqueline M Cliff, Christopher L Clayton, et al.
The Journal of Infectious Diseases|August 9, 2012
Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune responseJacqueline M Cliff, Ji-Sook Lee, Nicholas Constantinou, et al.
Microbiology (Reading, England)|October 9, 2002
Characterization of a Mycobacterium tuberculosis H37Rv transposon library reveals insertions in 351 ORFs and mutants with altered virulenceRuth A McAdam, Selwyn Quan, Debbie A Smith, et al.
Journal of Medicinal Chemistry|January 6, 2006
Structure-activity relationships at the 5-position of thiolactomycin: an intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coliPilho Kim, Yong-Mei Zhang, Gautham Shenoy, et al.
Tuberculosis (Edinburgh, Scotland)|July 24, 2012
Detection and treatment of subclinical tuberculosisBrian D Robertson, Danny Altmann, Clif Barry, et al.
Nature Medicine|July 6, 2021
The Tuberculosis Drug Accelerator at year 10: what have we learned?Bree B Aldridge, David Barros-Aguirre, Clifton E Barry, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2005
Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugsEdward A Weinstein, Takahiro Yano, Lin-Sheng Li, et al.
Nature Reviews. Drug Discovery|October 6, 2015
Hit and lead criteria in drug discovery for infectious diseases of the developing worldKei Katsuno, Jeremy N Burrows, Ken Duncan, et al.
Bioorganic & Medicinal Chemistry Letters|April 10, 2007
Evaluation of N-(phenylmethyl)-4-[5-(phenylmethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-4-yl]benzamide inhibitors of Mycobacterium tuberculosis growthMichael D Wall, Michael Oshin, Gavin A C Chung, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 24, 2004
Differential gene expression identifies novel markers of CD4+ and CD8+ T cell activation following stimulation by Mycobacterium tuberculosisJacqueline M Cliff, Iryna N J Andrade, Rohit Mistry, et al.
The Journal of Infectious Diseases|January 6, 2007
Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosisRohit Mistry, Jacqueline M Cliff, Christopher L Clayton, et al.
The Journal of Infectious Diseases|August 9, 2012
Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune responseJacqueline M Cliff, Ji-Sook Lee, Nicholas Constantinou, et al.
Microbiology (Reading, England)|October 9, 2002
Characterization of a Mycobacterium tuberculosis H37Rv transposon library reveals insertions in 351 ORFs and mutants with altered virulenceRuth A McAdam, Selwyn Quan, Debbie A Smith, et al.
Journal of Medicinal Chemistry|January 6, 2006
Structure-activity relationships at the 5-position of thiolactomycin: an intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coliPilho Kim, Yong-Mei Zhang, Gautham Shenoy, et al.
Tuberculosis (Edinburgh, Scotland)|July 24, 2012
Detection and treatment of subclinical tuberculosisBrian D Robertson, Danny Altmann, Clif Barry, et al.
Nature Medicine|July 6, 2021
The Tuberculosis Drug Accelerator at year 10: what have we learned?Bree B Aldridge, David Barros-Aguirre, Clifton E Barry, et al.
Pageof 3